<DOC>
	<DOC>NCT00746694</DOC>
	<brief_summary>The objective of this trial is to study the management of PPE in participants with metastatic ovarian or breast cancer treated with Caelyx, and determine the frequency of use of pharmacological treatment (preventive or therapeutic) for PPE and compliance of educational recommendations for PPE.</brief_summary>
	<brief_title>A Study to Determine the Management of Palmar-plantar Erythrodysesthesia (PPE) in Patients With Metastatic Ovarian or Breast Cancer Treated With Caelyx (Study P05020)</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Hand-Foot Syndrome</mesh_term>
	<mesh_term>Paresthesia</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<criteria>Women 18 years of age or older. Participants with metastatic breast or ovarian cancer who are receiving treatment with pegylated liposomal doxorubicin. Participants who have given their written consent. Participants who are currently participating in a clinical trial.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>